The International Atomic Energy Agency (IAEA) held the 3rd International Symposium on Trends in Radiopharmaceuticals, (ISTR-2023) at IAEA Headquarters in Vienna, Austria, during the week of 16–21 April 2023. This procedural paper summarizes highlights from symposium presentations, posters, panel discussions and satellite meetings, and provides additional resources that may be useful to researchers working with diagnostic and therapeutic radiopharmaceuticals in the academic, government and industry setting amongst IAEA Member States and beyond. More than 550 participants in person from 88 Member States attended the ISTR-2023. Over 360 abstracts were presented from all over the world by a diverse group of global scientists working with radiopharmaceuticals. Given this group of international radiochemists is unique to ISTR (IAEA funding enabled many to attend), there was an invaluable wealth of knowledge on the global state of the radiopharmaceutical sciences present at the meeting. The intent of this Proceedings paper is to share this snapshot from our international colleagues with the broader radiopharmaceutical sciences community by highlighting presentations from the conference on the following topics: Isotope Production and Radiochemistry, Industrial Insights, Regional Trends, Training and Education, Women in the Radiopharmaceutical Sciences, and Future Perspectives and New Initiatives. The authors of this paper are employees of IAEA, members of the ISTR-2023 Organizing Committee and/or members of the EJNMMI Radiopharmacy and Chemistry Editorial Board who attended ISTR-2023. Overall, ISTR-2023 fostered the successful exchange of scientific ideas around every aspect of the radiopharmaceutical sciences. It was well attended by a diverse mix of radiopharmaceutical scientists from all over the world, and the oral and poster presentations provided a valuable update on the current state-of-the-art of the field amongst IAEA Member States. Presentations as well as networking amongst the attendees resulted in extensive knowledge transfer amongst the various stakeholders representing 88 IAEA Member States. This was considered particularly valuable for attendees from Member States where nuclear medicine and the radiopharmaceutical sciences are still relatively new. Since the goal is for the symposium series to be held every four years; the next one is anticipated to take place in 2027.

中文翻译：

---

2023 年放射性药物趋势国际研讨会论文集 (ISTR-2023)

国际原子能机构 (IAEA) 于 2023 年 4 月 16 日至 21 日这一周在奥地利维也纳 IAEA 总部举办了第三届放射性药物趋势国际研讨会 (ISTR-2023)。本程序文件总结了研讨会演讲的要点，海报、小组讨论和卫星会议，并提供可能对原子能机构成员国及其他地区在学术、政府和工业界从事诊断和治疗放射性药物研究的研究人员有用的额外资源。来自 88 个成员国的 550 多名与会者亲自参加了 ISTR-2023。来自世界各地从事放射性药物研究的多元化科学家小组提交了 360 多份摘要。鉴于这群国际放射化学家是 ISTR 所独有的（国际原子能机构的资助使许多人能够参加），会议上有关于全球放射性药物科学状况的宝贵知识。本会议论文的目的是通过重点介绍会议中关于以下主题的演讲，与更广泛的放射性药物科学界分享我们的国际同事的这一快照：同位素生产和放射化学、工业见解、区域趋势、培训和教育、女性在放射性药物科学、未来展望和新举措。本文的作者是参加 ISTR-2023 的 IAEA 员工、ISTR-2023 组委会成员和/或 EJNMMI 放射药剂学和化学编辑委员会成员。总体而言，ISTR-2023 促进了围绕放射性药物科学各个方面的科学思想的成功交流。来自世界各地的各种放射性药物科学家出席了这次会议，口头和海报演讲提供了有关原子能机构成员国当前该领域最先进水平的宝贵最新信息。与会者的演讲和交流导致代表 88 个原子能机构成员国的各利益攸关方之间进行了广泛的知识转移。这对于来自核医学和放射性药物科学仍相对较新的成员国的与会者来说特别有价值。由于该系列研讨会的目标是每四年举办一次；下一次预计将于 2027 年举行。